Free Trial

RxSight Q2 2024 Earnings Report

RxSight logo
$29.60 -0.73 (-2.41%)
As of 02/21/2025 04:00 PM Eastern

RxSight EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.06
One Year Ago EPS
-$0.40

RxSight Revenue Results

Actual Revenue
$34.89 million
Expected Revenue
$32.33 million
Beat/Miss
Beat by +$2.56 million
YoY Revenue Growth
+67.60%

RxSight Announcement Details

Quarter
Q2 2024
Time
After Market Closes

RXST Upcoming Earnings

RxSight will be holding an earnings conference call on Tuesday, February 25 at 4:30 PM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Conference Call Audio

RxSight Earnings Headlines

Stifel Nicolaus Remains a Hold on RxSight (RXST)
Brokerages Set RxSight, Inc. (NASDAQ:RXST) Target Price at $58.13
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Insider Stock Buying Reaches US$1.83m On RxSight
RxSight price target lowered to $43 from $66 at Needham
See More RxSight Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RxSight? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RxSight and other key companies, straight to your email.

About RxSight

RxSight (NASDAQ:RXST), a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

View RxSight Profile

More Earnings Resources from MarketBeat